KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kymera Therapeutics Inc (KYMR) is not a strong buy for a beginner investor seeking long-term gains at this moment. While the stock has shown positive momentum and analyst optimism, the overbought RSI and lack of immediate catalysts suggest waiting for a better entry point. The financial performance and lack of significant trading trends also do not strongly support a buy decision right now.
The technical indicators show bullish momentum with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the RSI of 80.933 indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at R1: 84.17 and R2: 87.666, with support at S1: 72.851.
Multiple analysts have raised price targets significantly, with the highest being $
Positive Phase 1b results for KT-621 in atopic dermatitis have de-risked the program and increased investor confidence.
Bullish technical indicators and strong momentum.
Wolfe Research downgraded the stock to Peer Perform, citing valuation concerns and lack of immediate catalysts.
Financial performance shows a YoY revenue decline of -26.12%, and the company remains unprofitable.
RSI indicates overbought conditions, suggesting a potential short-term pullback.
In Q3 2025, revenue dropped by -26.12% YoY to $2.76M. However, net income improved by 31.51% YoY to -$82.18M, and EPS increased by 14.63% YoY to -0.94. Gross margin remains at 100%, but the company is still operating at a loss.
Analysts are generally positive on KYMR, with several raising price targets significantly after positive Phase 1b results. However, Wolfe Research downgraded the stock to Peer Perform, citing valuation concerns and lack of immediate catalysts. The highest price target is $133, while the lowest is $92.
